Protet-IG250 IU/ml

Protet-IG is a passive immunizing agent used in the prevention and management of tetanus.

Established / Approved Uses

• Post-exposure tetanus prophylaxis: Given after an injury (especially tetanus-prone wounds such as deep, contaminated, devitalized, or puncture wounds) in patients whose tetanus immunization history is incomplete, uncertain, or unknown, in combination with wound care and, where indicated, tetanus toxoid vaccine.
• Treatment of clinical (active) tetanus: Used as part of the combined management of diagnosed tetanus infection, together with wound debridement, antimicrobial therapy, airway/muscle spasm control, and supportive intensive care. Clinical trial evidence of benefit is limited, but it remains a standard-of-care adjunct recommended by treatment guidelines.

Important Note

Protet-IG provides only immediate, temporary (passive) protection against tetanus toxin. It does not replace active immunization; a course of tetanus toxoid-containing vaccine should be initiated or completed as appropriate, per standard wound-management and immunization protocols.

Human Tetanus Immunoglobulin is a sterile preparation of concentrated immunoglobulin G (IgG), containing tetanus antitoxin antibodies, purified from the pooled plasma of donors hyperimmunized with tetanus toxoid.

Each preparation is standardized and labeled in International Units (IU) of tetanus antitoxin activity per mL (commonly supplied as 250 IU per dose, in single-dose vials or prefilled syringes for intramuscular injection). It contains no antimicrobial preservative and no live organisms.

Protet-IG is a human plasma-derived biologic (a hyperimmune globulin) used for passive immunization against tetanus. Unlike tetanus toxoid vaccine, which stimulates the body's own immune system to produce antibodies over several weeks, Protet-IG supplies ready-made antibodies that give immediate, short-term protection.

It is prepared from the plasma of healthy donors with high levels of antibody to tetanus toxin, and is screened and processed to reduce the risk of transmitting infectious agents. It is administered by intramuscular injection and is used in emergency and hospital settings for wound management and treatment of tetanus.

Passive immunizing agent (Immunoglobulin / Hyperimmune globulin) - Protet-IG belongs to the class of human plasma-derived tetanus antitoxin preparations.

Mechanism: Human Tetanus Immunoglobulin contains preformed IgG antibodies directed against tetanus toxin (tetanospasmin), the neurotoxin produced by Clostridium tetani.

After intramuscular injection, these antibodies enter the circulation and bind to and neutralize circulating (free) tetanus toxin, preventing it from attaching to nerve tissue. Human Tetanus Immunoglobulin cannot neutralize toxin that has already become fixed to nerve tissue, which is why it is given as early as possible after injury or diagnosis.

Because the antibodies are passively transferred rather than produced by the patient's own immune system, protection is immediate but temporary, with a plasma half-life of approximately 3-4 weeks. This is in contrast to active immunization with tetanus toxoid, which produces longer-lasting immunity but takes time to develop.

Protet-IG is given by deep intramuscular injection only (e.g., into the anterolateral thigh or deltoid), never intravenously, due to the risk of anaphylactic-type reactions with IV administration.

When co-administered with tetanus toxoid vaccine, use different syringes and different injection sites (e.g., opposite limbs). Use with caution and applied pressure (rather than vigorous massage) at the injection site in patients with bleeding disorders or on anticoagulants, since it is an intramuscular product.

Live attenuated vaccines: Protet-IG can interfere with the immune response to live virus vaccines (e.g., measles, mumps, rubella, varicella). Administration of such vaccines should generally be deferred for approximately 3 months after receiving Protet-IG, unless otherwise directed by a physician.

Tetanus toxoid vaccine: Can be given at the same visit as Protet-IG without loss of efficacy of either product, provided they are given at separate sites with separate syringes (see Administration/Dosage).

Other immunoglobulin or blood products: Concurrent use of other antibody-containing blood products may affect antibody levels; spacing and clinical judgment by the physician are advised.

Most reactions to Protet-IG are mild and self-limited.

Common

• Pain, tenderness, redness, or swelling at the injection site
• Mild, transient fever
• Headache, malaise

Uncommon / Rare

• Angioedema, urticaria, or other hypersensitivity reactions
• Anaphylactic/anaphylactoid reactions (rare, more likely in IgA-deficient individuals - see Contraindications)
• Nephrotic syndrome (rare, reported with immunoglobulin products)
• Thromboembolic events (rare; see Precautions and Warnings)

Protet-IG should be used during pregnancy only if clearly needed, i.e., when the potential benefit (protection against a life-threatening infection) justifies the potential risk. Formal reproduction studies have not been conducted, and a well-established fetal risk has not been demonstrated; immunoglobulins are generally considered to cross the placenta in limited amounts. A physician should be consulted before use in pregnancy.

There is no specific evidence that Protet-IG is harmful during breastfeeding; as with any biologic product, it should be used in nursing mothers only under medical advice, weighing the clear benefit of tetanus prophylaxis/treatment against any theoretical risk.

• Route of administration: For intramuscular use only; intravenous administration may cause anaphylactic-type reactions.
• Bleeding disorders: Use with caution in patients with severe thrombocytopenia or other coagulation disorders in whom intramuscular injections are otherwise contraindicated, unless the expected benefit outweighs the risk of local bleeding.
• Plasma-derived product: Because Protet-IG is made from human plasma, it carries a theoretical risk of transmitting infectious agents (including viruses and, theoretically, the Creutzfeldt-Jakob disease agent) despite donor screening and viral inactivation/removal steps during manufacture. Report any suspected infection following administration to the prescribing physician.
• Thromboembolic events: Rare cases of thromboembolic events (e.g., myocardial infarction, stroke, deep vein thrombosis) have been reported with immunoglobulin products, particularly in patients with cardiovascular risk factors, advanced age, or immobility. Use with caution in such patients.
• Not a substitute for active immunization: Protet-IG provides only temporary, passive protection. Active immunization with tetanus toxoid-containing vaccine should also be addressed according to standard wound-management/immunization guidelines, since Protet-IG does not confer long-term immunity.
• Injection site: When given with tetanus toxoid vaccine, administer at a different site using separate syringes.

There is limited data on overdose with Protet-IG. If an excessive dose is administered or a suspected overdose reaction (such as a severe hypersensitivity reaction) occurs, seek immediate medical attention or contact emergency services. Management is supportive and symptomatic, provided in a healthcare setting; there is no specific antidote.

Store refrigerated at 2-8°C. Do not freeze; discard if the product has been frozen. Protect from light. Keep out of reach of children. Do not use after the expiry date printed on the pack.

Pediatric Use

Protet-IG is used in children, including those under 7 years of age, with weight-based dosing (approximately 4 units/kg) for tetanus prophylaxis, as detailed in Dosage and Administration. Use in neonates and infants should be guided by a pediatrician.

Elderly

No specific dose adjustment is established for elderly patients; use with caution in those with cardiovascular risk factors or reduced mobility due to a possible increased risk of thromboembolic events (see Precautions and Warnings).

Renal/Hepatic Impairment

No well-established dose adjustment is required for renal or hepatic impairment, as Protet-IG is a biologic immunoglobulin product rather than a renally or hepatically metabolized drug; use with the usual precautions in patients with significant organ dysfunction.

Immunocompromised Patients

May still require Protet-IG for tetanus prophylaxis/treatment; clinical judgment by the treating physician is advised, particularly regarding IgA deficiency (see Contraindications).

For tetanus prophylaxis, Protet-IG is typically given as a single intramuscular dose at the time of wound presentation. For treatment of active tetanus, dosing and duration are individualized by the treating specialist based on clinical severity and response, as part of a broader hospital treatment protocol; repeat dosing is occasionally used but must be guided by a physician.

Immunoglobulins; Passive immunizing agents; Hyperimmune globulins (human plasma-derived antitoxin preparations)

Human Tetanus Immunoglobulin supplies preformed antibodies (IgG) against tetanus toxin that circulate in the blood and neutralize free (unbound) tetanospasmin before it can attach to nerve tissue, providing immediate but temporary passive immunity, in contrast to the active, longer-lasting immunity produced by tetanus toxoid vaccination.

Protet-IG is used in pediatric patients, including those under 7 years old, for tetanus prophylaxis following tetanus-prone wounds when immunization status is incomplete or uncertain, using weight-based dosing (approximately 4 units/kg; see Dosage and Administration). Use in the treatment of active tetanus in children should be directed by a pediatric specialist. As with adults, Protet-IG does not replace the need for active immunization with tetanus toxoid where indicated.